Search alternatives:
larger decrease » marked decrease (Expand Search)
less decrease » teer decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
less decrease » teer decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
901
-
902
Influence of temperature and duration on the Tg of the cement/PA-12 powder mixture.
Published 2025Subjects: -
903
Contains R code utilized in the analyses.
Published 2024“…Spearman correlation analysis between the individuals’ calendar ages and cell type proportions revealed a statistically significant decrease in the proportion of neurons with increasing age. …”
-
904
-
905
Growth assessment parameters before and after biological treatment in the different studies.
Published 2025Subjects: -
906
-
907
-
908
-
909
-
910
-
911
Flow chart of experimental protocol.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
912
A representative ultrasound axis image.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
913
-
914
-
915
-
916
-
917
-
918
-
919
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
920
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”